Drug Trial Radar · NCT02573467
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Last checked: Nov 19, 2026Latest source record: Mar 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
211
Actual
Start
Nov 2, 2015
Primary completion
Aug 17, 2016
Study completion Feb 13, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 36 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This extension study will provide data to further evaluate the efficacy, safety, and tolerability of three doses of BYM338 and to assess the long-term effects of BYM338 in patients with sporadic inclusion body myositis. The extension study was planned to consist of a Screening epoch (to assess patient eligibility), followed by a Treatment Period 1 epoch (double-blind and placebo-controlled), and a Treatment Period 2 epoch (open-label). A Post-treatment Follow-up (FUP) epoch was also planned for patients who discontinued prematurely. Patients who complete the core study and qualify for this extension study entered Treatment Period 1 and continued on the study drug to which they were randomized in the core study (either to one of the three bimagrumab doses (1 mg/kg, 3 mg/kg, and 10mg/kg) or placebo) during Treatment Period 1. Thus, Treatment Period 1 was double-blind and placebo-controlled. Participants were to continue in Treatment Period 1 until the dose with the best benefit-risk profile was determined from the core study data and selected (duration of Treatment Period 1 was estimated to be between 6 and 8 months). Once the dose with the best benefit-risk profile was selected, all participants (including those who were receiving placebo) were planned to enter Treatment Period 2 and switch to open-label treatment with bimagrumab at the selected dose. The core study has been completed but since the core study did not meet the primary end point (no bimagrumab dose was identified based on the core study efficacy results) the extension study was terminated as per protocol/sponsor's decision; therefore, no patients had entered Treatment Period 2. Instead, all patients were to return for the End of Treatment Period 1 (EOT1) visit at their next scheduled visit. As per protocol, all patients who discontinued study medication during Treatment Period 1 for any reason, including due to the study having been stopped as per protocol/sponsor's decision, were to have entered and complete the 6-month FUP after their EOT1 visit. Due to the nature of the design of the core and extension studies and termination of study medication in the extension study, the treatment duration for individual patients varied considerably. Consequently, the number of patients contributing data to the efficacy analyses at Week 104 and later timepoints was decreased.
Conditions
- Sporadic Inclusion Body Myositis
Interventions
BimagrumabDrug
BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
PlaceboDrug
Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths.Time frame: to end of study (up to 14 months, including the 6-month treatment-free follow-up period)
- Change From Core Study Baseline in 6 Minute Walking Distance Test (6MWD)Time frame: Core study baseline, weeks 52, 78, 104, and >=117
Locations
38 sites in 10 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Phoenix, Arizona
Novartis Investigative Site
Orange, California
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Miami, Florida
Novartis Investigative Site
Kansas City, Kansas
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Columbus, Ohio
Novartis Investigative Site
Portland, Oregon
Novartis Investigative Site
Dallas, Texas
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
St Leonards, New South Wales, Australia
Novartis Investigative Site
Cauldfield, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Edegem, Antwerpen, Belgium
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Messina, ME, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Padova, PD, Italy
Novartis Investigative Site
Tokushima, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Kumamoto, Kumamoto, Japan
Novartis Investigative Site
Sendai, Miyagi, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Novartis Investigative Site
Kodaira, Tokyo, Japan
Novartis Investigative Site
Wakayama, Wakayama, Japan
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Leiden, Netherlands
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Newcastle upon Tyne, United Kingdom
Novartis Investigative Site
Salford, Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.